Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy
Study identifier:D5551R00012
ClinicalTrials.gov identifier:NCT02843399
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Clinical and Economic Outcomes of Patients with Type 2 Diabetes Mellitus initiating Bydureon and Glargine
Medical condition
Diabetes mellitus type 2
Phase
-
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
15498
Study type
Observational
Age
18 Years - 99 Years
Date
Study Start Date: 15 Aug 2016
Primary Completion Date: 15 Dec 2016
Study Completion Date: 15 Dec 2016
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Dec 2017 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
Truven Health
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Exenatide once weekly (EQW) EQW cohort includes patients with one or more outpatient prescription claims for EQW between 2012 and 2015. | - |
| Insulin Glargine (IG) IG cohort includes patients with one or more outpatient prescription claims for IG between 2012 and 2015 | - |
Contacts
Investigators
Principal Investigator
Eric T. Wittbrodt
AstraZeneca
